Dr. Robert Driscoll
Recent Articles
MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA 05/06/2026
Wedbush Securities downgraded Replimune Group Inc. (NASDAQ:REPL) to NEUTRAL after the FDA issued a second complete response letter for RP1 in PD-1 refractory melanoma.
Boston Biotech Announces Novartis Collaboration 10/28/2024
Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) recently unveiled a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program, according to a Wedbush research note.
Due to permission requirements, not all quotes are shown.
